Colon Cancer: a new therapeutic breakthrough?

Colorectal cancer (CRC) ranks among the most common and deadly cancers worldwide. Despite therapeutic advances, particularly through the combination of surgery and chemotherapy, two major challenges persist: treatment resistance and tumor recurrence. Addressing these limitations, an innovative strategy has emerged: combining the inhibition of O-GlcNAcylation, a key post-translational modification, with reduced doses of chemotherapy. The goal? To redirect cancer cell responses toward apoptosis, a process that promotes their elimination, rather than senescence, which fosters relapse and cancer progression.